US courts restrict abortion drug access while FDA approves breakthrough cancer therapies and explores psychedelic treatments, as healthcare systems grapple with specialist integration and innovative diabetes approaches emerge.

A U.S. appeals court temporarily blocked a federal rule allowing the abortion drug mifepristone to be dispensed through the mail, significantly curtailing patient access to the medication despite previous FDA authorization of mail-order distribution.

The FDA authorized expanded access to daraxonrasib, an oral RAS(ON) inhibitor for pancreatic cancer, after the drug doubled survival rates for metastatic patients in phase 3 clinical trials, potentially offering hope to treatment-resistant cases.

Vepdegestrant received FDA approval for ESR1-mutated breast cancer based on the phase 3 VERITAC-2 trial demonstrating significantly improved progression-free survival, expanding treatment options for this specific genetic subtype.

A new FDA regulatory pathway is accelerating psychedelic therapy approvals, with experts suggesting psilocybin-based treatments from companies like Compass Pathways could be among the first approved for resistant depression and PTSD.

A Royal College of Physicians survey revealed that nearly half of specialist doctors are uncertain about their role in the UK's new neighborhood health teams, raising concerns about specialist integration into reformed NHS structures.

Researchers proposed a new staging system for advanced cutaneous squamous cell carcinoma that provides better discrimination between disease progression and mortality compared to current standard classification methods.

Sirolimus-eluting balloons demonstrated comparable performance to standard care for repeat coronary in-stent restenosis at one year, though drug-eluting stents remain superior for single-layer disease in coronary interventions.

Scientists created 'cyborg' organoids by combining electronic sensors with human islet cells, generating previously unavailable data on islet cell function that could accelerate development of novel diabetes therapies.